AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12802837 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered medication program
Number of subjects: 350
Study 12802837 — intervention group
Group type: COMPARATOR
Intervention: Nurse-administered medications
Number of subjects: 350
Study 10373999 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus telephone counselling (intervention group)
Number of subjects: 396
Study 10373999 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 396
Study 8558208 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg ibandronate
Number of subjects: 174
Study 8558208 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1 mg ibandronate
Number of subjects: 174
Study 8558208 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg ibandronate
Number of subjects: 174
Study 1757027 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronic acid
Number of subjects: 200
Study 1757027 — intervention group
Group type: COMPARATOR
Intervention: Hydroxypropylmethyl cellulose (HPMC)
Number of subjects: 200
Study 6625031 — intervention group
Group type: EXPERIMENTAL
Intervention: Richmond/Hopkins Family Coping Index with revised operational guidelines
Number of subjects: 0
Study 30982776 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine (internet-based video counseling)
Number of subjects: 115
Study 30982776 — intervention group
Group type: COMPARATOR
Intervention: Control (standard face-to-face clinical visit)
Number of subjects: 115
Study 28145842 — intervention group
Group type: EXPERIMENTAL
Intervention: Otoscopy Simulation (OS)
Number of subjects: 54
Study 28145842 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-Based Module (WM)
Number of subjects: 54
Study 28145842 — intervention group
Group type: COMPARATOR
Intervention: Standard Instruction (SI)
Number of subjects: 54
Study 27087080 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantago ovata husk
Number of subjects: 0
Study 27087080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24889138 — intervention group
Group type: EXPERIMENTAL
Intervention: Figure 8 FlatWire
Number of subjects: 63
Study 24889138 — intervention group
Group type: COMPARATOR
Intervention: Steel wire cerclage
Number of subjects: 63
Study 22422593 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfracture (MF)
Number of subjects: 70
Study 22422593 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteochondral autograft transplantation (OAT)
Number of subjects: 70
Study 22422593 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous chondrocyte implantation (ACI)
Number of subjects: 70
Study 20946444 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured discharge education
Number of subjects: 59
Study 20946444 — intervention group
Group type: COMPARATOR
Intervention: Traditional discharge education (Control)
Number of subjects: 59
Study 17332026 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial electrical cardioversion (ECV) and serial antiarrhythmic drug strategy in patients with systolic heart failure
Number of subjects: 64
Study 17332026 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without heart failure)
Number of subjects: 64
Study 17332026 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial ECV and antiarrhythmic drug approach in patients with systolic heart failure
Number of subjects: 64
Study 15810945 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice (n = 97)
Number of subjects: 189
Study 15810945 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 92)
Number of subjects: 189
Study 12378376 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for hypertension
Number of subjects: 1866
Study 12378376 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for hypertension in microalbuminuric patients
Number of subjects: 1866
Study 12378376 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for hypertension in macroalbuminuric patients
Number of subjects: 1866
Study 12378376 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of more than one anti-hypertensive drug
Number of subjects: 1866
Study 12378376 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of ACE inhibitors
Number of subjects: 1866
Study 9473754 — intervention group
Group type: EXPERIMENTAL
Intervention: VACA (vincristine/actinomycin D/cyclophosphamide/adriamycin)
Number of subjects: 61
Study 9473754 — intervention group
Group type: COMPARATOR
Intervention: VACAD (VACA plus imidazole carboxamide (DTIC))
Number of subjects: 61
Study 9473754 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III disease (regional unresected)
Number of subjects: 61
Study 9473754 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 1 and 2 histology
Number of subjects: 61
Study 8568022 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner-support, incentive-based educational program
Number of subjects: 68
Study 8568022 — intervention group
Group type: COMPARATOR
Intervention: Usual breast feeding (control)
Number of subjects: 68
Study 2245548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative irrigation of long‐acting dexamethasone before incision closure
Number of subjects: 45
Study 2245548 — intervention group
Group type: COMPARATOR
Intervention: Standard operative procedure (control group)
Number of subjects: 45
Study 2245548 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid group
Number of subjects: 45
Study 221812 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon (7 x 10(4) U/kg/day for 5 days)
Number of subjects: 37
Study 221812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 221812 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon
Number of subjects: 37
Study 31754239 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically increased serum uric acid
Number of subjects: 10000
Study 31754239 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 10000
Study 30699287 — intervention group
Group type: EXPERIMENTAL
Intervention: Target enrichment method for identifying non-reference L1Hs
Number of subjects: 1
Study 30699287 — intervention group
Group type: EXPERIMENTAL
Intervention: Target enrichment method
Number of subjects: 1
Study 28353056 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg oral psilocybin
Number of subjects: 12
Study 28353056 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 mg/kg oral psilocybin
Number of subjects: 12
Study 28353056 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg oral psilocybin
Number of subjects: 12
Study 25496000 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated microneedle radiofrequency (FMR)
Number of subjects: 25
Study 25496000 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 25
Study 23407049 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line monotherapy capecitabine
Number of subjects: 268
Study 23407049 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine-irinotecan combination therapy
Number of subjects: 268
Study 23407049 — intervention group
Group type: COMPARATOR
Intervention: MTHFR 1298A>C and 677C>T genotypes
Number of subjects: 268
Study 21971929 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-enhanced colonoscopy (HD-NBI)
Number of subjects: 96
Study 21971929 — intervention group
Group type: COMPARATOR
Intervention: Standard definition white light colonoscopy (SDWL)
Number of subjects: 96
Study 19820812 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory flow increase technique (EFIT)
Number of subjects: 81
Study 19820812 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration accompanied by postural drainage (PD)
Number of subjects: 81
Study 19820812 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study 16735941 — intervention group
Group type: EXPERIMENTAL
Intervention: EA 1.8 mg/day
Number of subjects: 552
Study 16735941 — intervention group
Group type: EXPERIMENTAL
Intervention: EA 0.9 mg/day
Number of subjects: 552
Study 16735941 — intervention group
Group type: EXPERIMENTAL
Intervention: EA 0.45 mg/day
Number of subjects: 552
Study 16735941 — intervention group
Group type: EXPERIMENTAL
Intervention: EA 0.9 mg/day and EA 1.8 mg/day
Number of subjects: 552
Study 16735941 — intervention group
Group type: EXPERIMENTAL
Intervention: All EA groups
Number of subjects: 552
Study 16735941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 552
Study 15316247 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11210885 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic artificial source of voice incorporated in a regular tracheoesophageal (TE) shunt valve
Number of subjects: 6
Study 11210885 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic artificial source of voice
Number of subjects: 6
Study 9149451 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined condition
Number of subjects: 77
Study 9149451 — intervention group
Group type: EXPERIMENTAL
Intervention: Influence condition
Number of subjects: 77
Study 9149451 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Consequences condition
Number of subjects: 77
Study 9149451 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 77
Study 8425345 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pulsed electromagnetic fields (PEMFs) treatment
Number of subjects: 37
Study 8425345 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo) treatment
Number of subjects: 37
Study 3315579 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC 15U
Number of subjects: 50
Study 3315579 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC 20U
Number of subjects: 50
Study 3315579 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC 25U
Number of subjects: 50
Study 3315579 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC 30U
Number of subjects: 50
Study 3315579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30861537 — intervention group
Group type: EXPERIMENTAL
Intervention: Allograft bone chips mixed with autologous bone marrow (BM) in 19 patients (group A)
Number of subjects: 36
Study 30861537 — intervention group
Group type: COMPARATOR
Intervention: Allograft bone chips only in 17 patients (group B)
Number of subjects: 36
Study 30861537 — intervention group
Group type: EXPERIMENTAL
Intervention: Allograft bone chips mixed with autologous BM in group A
Number of subjects: 36
Study 30861537 — intervention group
Group type: COMPARATOR
Intervention: Allograft bone chips only in group B
Number of subjects: 36
Study 30861537 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 36
Study 30239290 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexercise BFR (30% RP)
Number of subjects: 10
Study 30239290 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR during exercise (30% RD)
Number of subjects: 10
Study 30239290 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy REx (75% 1RM)
Number of subjects: 10
Study 30239290 — intervention group
Group type: COMPARATOR
Intervention: Traditional low-load BFR REx (30%)
Number of subjects: 10
Study 26813845 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for insomnia (CBTi)
Number of subjects: 31
Study 26813845 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 31
Study 24218307 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exchange
Number of subjects: 672
Study 24218307 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 672
Study 22067982 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation plus standard of care
Number of subjects: 20
Study 22067982 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 20
Study 20377796 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentiality education program
Number of subjects: 59
Study 20377796 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 59
Study 18992162 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (one cycle)
Number of subjects: 0
Study 18992162 — intervention group
Group type: COMPARATOR
Intervention: Radiation Therapy (RT)
Number of subjects: 0
Study 16531163 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinylestradiol 15 mug/gestodene 60 mug (EE/GST)
Number of subjects: 80
Study 16531163 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinylestradiol 30 mug/drospirenone 3 mg (EE/DRS)
Number of subjects: 80
Study 16531163 — intervention group
Group type: COMPARATOR
Intervention: male condom (control group)
Number of subjects: 80
Study 14584297 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide or indapamide treatment
Number of subjects: 0
Study 14584297 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 0
Study 14584297 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate (without sodium)
Number of subjects: 0
Study 10950230 — intervention group
Group type: EXPERIMENTAL
Intervention: Bug-busting (wet combing with a fine-toothed comb) every 3-4 days for 2 weeks
Number of subjects: 72
Study 10950230 — intervention group
Group type: COMPARATOR
Intervention: Malathion lotion (0.5%) applied twice, 7 days apart
Number of subjects: 72
Study 8825255 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated service agencies (ISAs) with financing reform and assertive continuous treatment team approach
Number of subjects: 0
Study 8825255 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated service agencies (ISAs)
Number of subjects: 0
Study 8825255 — intervention group
Group type: COMPARATOR
Intervention: Comparison groups receiving usual services
Number of subjects: 0
Study 1563207 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidisomide (SC-40230) intravenous doses ranging from 0.03 to 2.5 mg/kg
Number of subjects: 49
Study 1563207 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidisomide (SC-40230) 2.0 mg/kg orally and intravenously
Number of subjects: 49
Study 1563207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 6362417 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraperitoneal cesarean section plus prophylactic antibiotics (group C)
Number of subjects: 91
Study 6362417 — intervention group
Group type: COMPARATOR
Intervention: Transperitoneal primary cesarean section (control group)
Number of subjects: 91
Study 6362417 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraperitoneal cesarean section (group A)
Number of subjects: 91
Study 6362417 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraperitoneal cesarean section (group B)
Number of subjects: 91
Study 31066956 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral bulking therapy
Number of subjects: 0
Study 29629400 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 400 µg twice daily
Number of subjects: 0
Study 26974022 — intervention group
Group type: EXPERIMENTAL
Intervention: IT hydromorphone at ED90 of 75 μg
Number of subjects: 80
Study 26974022 — intervention group
Group type: COMPARATOR
Intervention: IT morphine at ED90 of 150 μg
Number of subjects: 80
Study 26974022 — intervention group
Group type: EXPERIMENTAL
Intervention: IT hydromorphone (ED90 or higher)
Number of subjects: 80
Study 26974022 — intervention group
Group type: COMPARATOR
Intervention: IT morphine (ED90 or higher)
Number of subjects: 80
Study 26974022 — intervention group
Group type: EXPERIMENTAL
Intervention: IT hydromorphone and IT morphine
Number of subjects: 80
Study 24611935 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO+PRO
Number of subjects: 60
Study 24611935 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO+PROh
Number of subjects: 60
Study 24611935 — intervention group
Group type: COMPARATOR
Intervention: CHO
Number of subjects: 60
Study 22964561 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behaviour Therapy (DBT) for 12 months
Number of subjects: 80
Study 22964561 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 80
Study 22964561 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT (completed treatment)
Number of subjects: 80
Study 22964561 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT (non-completers)
Number of subjects: 80
Study 20406655 — intervention group
Group type: EXPERIMENTAL
Intervention: US obesity prevention intervention
Number of subjects: 506
Study 20406655 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 506
Study 17928325 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 15 mg/kg/day for 2 weeks
Number of subjects: 43
Study 17928325 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cysticidal therapy)
Number of subjects: 43
Study 15994046 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US)
Number of subjects: 89
Study 12477681 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl infusion at a rate of 0.75, 1.0, or 1.5 microg x kg(‐1) x min(‐1)
Number of subjects: 60
Study 12477681 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil infusion at a rate of 0.75, 1.0, or 1.5 microg x kg(‐1) x min(‐1)
Number of subjects: 60
Study 10614716 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alpha therapy
Number of subjects: 18
Study 8556997 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium as a priming agent
Number of subjects: 0
Study 8556997 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium as a priming agent
Number of subjects: 0
Study 8556997 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium and vecuronium as priming agents
Number of subjects: 0
Study 1930849 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mmol Mg added to a free diet for 6 months
Number of subjects: 71
Study 6284661 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg/day
Number of subjects: 10
Study 6284661 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (various doses)
Number of subjects: 10
Study 6284661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31478919 — intervention group
Group type: EXPERIMENTAL
Intervention: Social contact person engaged by phone (intervention)
Number of subjects: 399
Study 31478919 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 399
Study 30135389 — intervention group
Group type: EXPERIMENTAL
Intervention: High walkability areas
Number of subjects: 731
Study 30135389 — intervention group
Group type: COMPARATOR
Intervention: Low walkability areas
Number of subjects: 731
Study 30135389 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 731
Study 30135389 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban and suburban areas
Number of subjects: 731
Study 30135389 — intervention group
Group type: COMPARATOR
Intervention: Rural area
Number of subjects: 731
Study 26727718 — intervention group
Group type: EXPERIMENTAL
Intervention: Information on overdiagnosis
Number of subjects: 586
Study 26727718 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior awareness of overdiagnosis
Number of subjects: 586
Study 26727718 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education level and Medical Aid Program
Number of subjects: 586
Study 26727718 — intervention group
Group type: EXPERIMENTAL
Intervention: Stronger beliefs on efficacy of cancer screening
Number of subjects: 586
Study 24203062 — intervention group
Group type: EXPERIMENTAL
Intervention: 17β‐estradiol (E2)
Number of subjects: 24
Study 24203062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 24203062 — intervention group
Group type: EXPERIMENTAL
Intervention: 17β‐estradiol (E2) with GHRH
Number of subjects: 24
Study 24203062 — intervention group
Group type: COMPARATOR
Intervention: Placebo with GHRH
Number of subjects: 24
Study 22331756 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir granule (test) 100 mg
Number of subjects: 20
Study 22331756 — intervention group
Group type: COMPARATOR
Intervention: Cefdinir capsule (reference) 100 mg
Number of subjects: 20
Study 19700248 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation plus intensity‐modulated radiotherapy (Arm B)
Number of subjects: 259
Study 19700248 — intervention group
Group type: COMPARATOR
Intervention: Conventional (tangential field) fractionated whole breast treatment (Arm A)
Number of subjects: 259
Study 17427522 — intervention group
Group type: EXPERIMENTAL
Intervention: VCD (video compact disc) demonstrating nasogastric intubation
Number of subjects: 61
Study 17427522 — intervention group
Group type: COMPARATOR
Intervention: Control group (no VCD)
Number of subjects: 61
Study 15378675 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (0.5 mg/kg)
Number of subjects: 12
Study 15378675 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (0.2 mg/kg)
Number of subjects: 12
Study 15378675 — intervention group
Group type: COMPARATOR
Intervention: Cocaine (0.2 mg/kg)
Number of subjects: 12
Study 11473079 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 4 ng.kg(‐1).min(‐1) for 16 h/day
Number of subjects: 40
Study 11473079 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 4 ng.kg(‐1).min(‐1) for 24 h/day
Number of subjects: 40
Study 11473079 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 8 ng.kg(‐1).min(‐1) for 16 h/day
Number of subjects: 40
Study 9869503 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedisamil dihydrochloride administered intravenously
Number of subjects: 9
Study 7759146 — intervention group
Group type: EXPERIMENTAL
Intervention: BioLogic-DT sorbent suspension dialyser
Number of subjects: 10
Study 2856651 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous human growth hormone releasing factor (hGRF) (1 microgram/kg in 5 cc of normal saline infused over five minutes)
Number of subjects: 16
Study 2856651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2856651 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous human growth hormone releasing factor (hGRF)
Number of subjects: 16
Study 30965599 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐A combined with a four‐week ankle isokinetic treatment (n = 12)
Number of subjects: 25
Study 30965599 — intervention group
Group type: COMPARATOR
Intervention: BoNT‐A alone (n = 13)
Number of subjects: 25